Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.

Negandhi AA, Hyde A, Dicks E, Pollett W, Younghusband BH, Parfrey P, Green RC, Savas S.

PLoS One. 2013 Apr 23;8(4):e61469. doi: 10.1371/journal.pone.0061469. Print 2013.

2.

Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.

Gusella M, Frigo AC, Bolzonella C, Marinelli R, Barile C, Bononi A, Crepaldi G, Menon D, Stievano L, Toso S, Pasini F, Ferrazzi E, Padrini R.

Br J Cancer. 2009 May 19;100(10):1549-57. doi: 10.1038/sj.bjc.6605052. Epub 2009 Apr 21.

3.

Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China.

Zhu L, Wang F, Hu F, Wang Y, Li D, Dong X, Cui B, Zhao Y.

Med Oncol. 2013 Mar;30(1):467. doi: 10.1007/s12032-013-0467-1. Epub 2013 Feb 8.

PMID:
23392576
4.

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

Etienne MC, Formento JL, Chazal M, Francoual M, Magné N, Formento P, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G.

Pharmacogenetics. 2004 Dec;14(12):785-92.

PMID:
15608557
5.

Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.

Afzal S, Gusella M, Vainer B, Vogel UB, Andersen JT, Broedbaek K, Petersen M, Jimenez-Solem E, Bertolaso L, Barile C, Padrini R, Pasini F, Jensen SA, Poulsen HE.

Clin Cancer Res. 2011 Jun 1;17(11):3822-9. doi: 10.1158/1078-0432.CCR-11-0304. Epub 2011 Apr 6.

6.

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A.

Br J Clin Pharmacol. 2010 Jan;69(1):58-66. doi: 10.1111/j.1365-2125.2009.03556.x.

7.

Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.

Fernández-Peralta AM, Daimiel L, Nejda N, Iglesias D, Medina Arana V, González-Aguilera JJ.

Int J Colorectal Dis. 2010 Feb;25(2):141-51. doi: 10.1007/s00384-009-0779-y. Epub 2009 Aug 11.

PMID:
19669769
8.

Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population.

Jang MJ, Kim JW, Jeon YJ, Chong SY, Hong SP, Hwang SG, Oh D, Cho YK, Ji YG, Kim NK.

Gene. 2014 Jan 10;533(2):558-64. doi: 10.1016/j.gene.2013.09.056. Epub 2013 Oct 5.

PMID:
24100087
9.

Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer.

Wu NC, Su SM, Lin TJ, Chin J, Hou CF, Yang JY, Liu WS, Chang LC.

Anticancer Drugs. 2015 Sep;26(8):888-93. doi: 10.1097/CAD.0000000000000261.

PMID:
26111049
10.

MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.

Afzal S, Jensen SA, Vainer B, Vogel U, Matsen JP, Sørensen JB, Andersen PK, Poulsen HE.

Ann Oncol. 2009 Oct;20(10):1660-6. doi: 10.1093/annonc/mdp046. Epub 2009 May 22.

PMID:
19465420
11.

Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.

Hitre E, Budai B, Adleff V, Czeglédi F, Horváth Z, Gyergyay F, Lövey J, Kovács T, Orosz Z, Láng I, Kásler M, Kralovánszky J.

Pharmacogenet Genomics. 2005 Oct;15(10):723-30.

PMID:
16141798
12.

Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?

Suh KW, Kim JH, Kim DY, Kim YB, Lee C, Choi S.

Ann Surg Oncol. 2006 Nov;13(11):1379-85. Epub 2006 Sep 29.

PMID:
17009149
13.

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

Marcuello E, Altés A, Menoyo A, Rio ED, Baiget M.

Cancer Chemother Pharmacol. 2006 Jun;57(6):835-40. Epub 2005 Sep 27.

PMID:
16187112
14.

The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.

Huang ZH, Hua D, Li LH.

Cancer Chemother Pharmacol. 2009 Apr;63(5):911-8. doi: 10.1007/s00280-008-0815-6. Epub 2008 Aug 15.

PMID:
18704422
15.

Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.

Sun K, Gong A, Liang P.

Tumour Biol. 2015 Mar;36(3):1549-59. doi: 10.1007/s13277-014-2721-3. Epub 2014 Oct 30.

PMID:
25355595
16.

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ, Iacopetta B.

Br J Cancer. 2009 Sep 15;101(6):998-1004. doi: 10.1038/sj.bjc.6605239. Epub 2009 Aug 11.

17.

Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.

Chen J, Luo X, Xie G, Chen K, Jiang H, Pan F, Li J, Ruan Z, Pang X, Liang H.

Medicine (Baltimore). 2016 May;95(19):e3652. doi: 10.1097/MD.0000000000003652.

18.

Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.

Lai CY, Sung FC, Hsieh LL, Tang R, Chiou HY, Wu FY, Yeh CC.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S599-606. doi: 10.1245/s10434-013-3069-4. Epub 2013 Jun 26.

PMID:
23800895
19.

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.

Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, Clarke SJ.

Clin Cancer Res. 2008 Feb 1;14(3):817-25. doi: 10.1158/1078-0432.CCR-07-0425.

20.

[Polymorphism of methylenetetrahydrofolate reductase and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy].

Gao CM, Lu JW, Toshiro T, Wu JZ, Cao HX, Chen HQ, Feng JF, Kazuo T.

Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Dec;25(12):1054-8. Chinese.

PMID:
15769364

Supplemental Content

Support Center